Questions & Answers

A major breakthrough announced in late 2025 and scaling in 2026 is the Hybrid Lyme ELISA developed by Kephera Diagnostics.

• 90% Early Sensitivity: Unlike traditional two-step tests, this AI-driven single-tier test identifies over 90% of patients even in the very early "bullseye rash" stage.

• Mechanism: It uses a novel immunoassay principle where antibody molecules bind to two antigens simultaneously—a process previously unseen in infectious disease diagnostics.

• Clinical Impact: This allows clinicians to move straight to treatment without waiting for "seroconversion" (the weeks it takes for the body to produce enough antibodies for old tests to detect).